Baidu
map

JACC:生物瓣膜血栓形成患者远期的抗凝预后研究

2020-02-26 不详 MedSci原创

在生物瓣膜血栓形成(BPVT)的早期预防和治疗中,抗凝是有效的,但BPVT后的长期疗效尚不清楚。本研究的目的旨在评估接受抗凝治疗的BPVT患者的远期预后。本研究纳入分析了83名因疑似BPVT接受华法林治疗的患者(平均年龄57±18岁,男性占54%),并与166名匹配对照进行对比分析。有62名患者在抗凝治疗后的3个月内心超结果转为正常,21名患者对华法林无反应。经过平均34个月时间的随访,病例组和对

在生物瓣膜血栓形成(BPVT)的早期预防和治疗中,抗凝是有效的,但BPVT后的长期疗效尚不清楚。本研究的目的旨在评估接受抗凝治疗的BPVT患者的远期预后。

本研究纳入分析了83名因疑似BPVT接受华法林治疗的患者(平均年龄57±18岁,男性占54%),并与166名匹配对照进行对比分析。有62名患者在抗凝治疗后的3个月内心超结果转为正常,21名患者对华法林无反应。经过平均34个月时间的随访,病例组和对照组之间在主要终点事件方面无明显差异(p = 0.79),但是BPVT组患者的大出血风险更高(12% vs. 2%; p < 0.0001),有14名患者在随访23个月后出现了BPVT的复发,仅一名复发患者对华法林有反应。另外,BPVT患者的瓣膜再置换率更高。

研究结果显示,生物瓣膜血栓形成有相当一部分患者会出现BPVT再复发和早期的假体再退化。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854669, encodeId=882518546698b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Aug 06 22:04:00 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635561, encodeId=45261635561b8, content=<a href='/topic/show?id=83a3693965d' target=_blank style='color:#2F92EE;'>#生物瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69396, encryptionId=83a3693965d, topicName=生物瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddce22497218, createdName=396094184_42047362, createdTime=Sat Jan 23 05:04:00 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326500, encodeId=d0b113265005f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Feb 28 04:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399095, encodeId=e90213990950c, content=<a href='/topic/show?id=49dd69399c2' target=_blank style='color:#2F92EE;'>#生物瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69399, encryptionId=49dd69399c2, topicName=生物瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/SicjCIAeTxGf3PibxsFPgEb3xtbibdR8KpjNN5V3XkiatR1BXv2o9YPVhSnazedCHtUUh9KJyUmqYnmS3fRlyJZ4Dw/132, createdBy=5c342186905, createdName=liao1620, createdTime=Fri Feb 28 04:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583654, encodeId=37241583654be, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Feb 28 04:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=)]
    2020-08-06 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854669, encodeId=882518546698b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Aug 06 22:04:00 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635561, encodeId=45261635561b8, content=<a href='/topic/show?id=83a3693965d' target=_blank style='color:#2F92EE;'>#生物瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69396, encryptionId=83a3693965d, topicName=生物瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddce22497218, createdName=396094184_42047362, createdTime=Sat Jan 23 05:04:00 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326500, encodeId=d0b113265005f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Feb 28 04:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399095, encodeId=e90213990950c, content=<a href='/topic/show?id=49dd69399c2' target=_blank style='color:#2F92EE;'>#生物瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69399, encryptionId=49dd69399c2, topicName=生物瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/SicjCIAeTxGf3PibxsFPgEb3xtbibdR8KpjNN5V3XkiatR1BXv2o9YPVhSnazedCHtUUh9KJyUmqYnmS3fRlyJZ4Dw/132, createdBy=5c342186905, createdName=liao1620, createdTime=Fri Feb 28 04:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583654, encodeId=37241583654be, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Feb 28 04:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854669, encodeId=882518546698b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Aug 06 22:04:00 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635561, encodeId=45261635561b8, content=<a href='/topic/show?id=83a3693965d' target=_blank style='color:#2F92EE;'>#生物瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69396, encryptionId=83a3693965d, topicName=生物瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddce22497218, createdName=396094184_42047362, createdTime=Sat Jan 23 05:04:00 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326500, encodeId=d0b113265005f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Feb 28 04:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399095, encodeId=e90213990950c, content=<a href='/topic/show?id=49dd69399c2' target=_blank style='color:#2F92EE;'>#生物瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69399, encryptionId=49dd69399c2, topicName=生物瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/SicjCIAeTxGf3PibxsFPgEb3xtbibdR8KpjNN5V3XkiatR1BXv2o9YPVhSnazedCHtUUh9KJyUmqYnmS3fRlyJZ4Dw/132, createdBy=5c342186905, createdName=liao1620, createdTime=Fri Feb 28 04:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583654, encodeId=37241583654be, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Feb 28 04:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854669, encodeId=882518546698b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Aug 06 22:04:00 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635561, encodeId=45261635561b8, content=<a href='/topic/show?id=83a3693965d' target=_blank style='color:#2F92EE;'>#生物瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69396, encryptionId=83a3693965d, topicName=生物瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddce22497218, createdName=396094184_42047362, createdTime=Sat Jan 23 05:04:00 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326500, encodeId=d0b113265005f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Feb 28 04:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399095, encodeId=e90213990950c, content=<a href='/topic/show?id=49dd69399c2' target=_blank style='color:#2F92EE;'>#生物瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69399, encryptionId=49dd69399c2, topicName=生物瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/SicjCIAeTxGf3PibxsFPgEb3xtbibdR8KpjNN5V3XkiatR1BXv2o9YPVhSnazedCHtUUh9KJyUmqYnmS3fRlyJZ4Dw/132, createdBy=5c342186905, createdName=liao1620, createdTime=Fri Feb 28 04:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583654, encodeId=37241583654be, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Feb 28 04:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854669, encodeId=882518546698b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Aug 06 22:04:00 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635561, encodeId=45261635561b8, content=<a href='/topic/show?id=83a3693965d' target=_blank style='color:#2F92EE;'>#生物瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69396, encryptionId=83a3693965d, topicName=生物瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddce22497218, createdName=396094184_42047362, createdTime=Sat Jan 23 05:04:00 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326500, encodeId=d0b113265005f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Feb 28 04:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399095, encodeId=e90213990950c, content=<a href='/topic/show?id=49dd69399c2' target=_blank style='color:#2F92EE;'>#生物瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69399, encryptionId=49dd69399c2, topicName=生物瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/SicjCIAeTxGf3PibxsFPgEb3xtbibdR8KpjNN5V3XkiatR1BXv2o9YPVhSnazedCHtUUh9KJyUmqYnmS3fRlyJZ4Dw/132, createdBy=5c342186905, createdName=liao1620, createdTime=Fri Feb 28 04:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583654, encodeId=37241583654be, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Feb 28 04:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=)]

相关资讯

盘点:JACC2月第四期研究一览

1.长期暴露于PM2.5会增加心血管疾病发生风险DOI: 10.1016/j.jacc.2019.12.031http://www.onlinejacc.org/content/75/7长期接触细颗粒物(PM2.5)对心血管疾病(CVDs)的影响,在中国和其他同样高水平的国家中尚未完全阐明。本研究的目的旨在评估中国PM2.5对CVD发生的长期影响。本研究纳入分析了China-PAR临床研究中的11

JACC:长期暴露于PM2.5会增加心血管疾病发生风险

长期接触细颗粒物(PM2.5)对心血管疾病(CVDs)的影响,在中国和其他同样高水平的国家中尚未完全阐明。本研究的目的旨在评估中国PM2.5对CVD发生的长期影响。本研究纳入分析了China-PAR临床研究中的116972名无基础心血管疾病的参与者,随访时间为15年。China-PAR临床研究中的PM2.5监测点每年的平均PM2.5浓度为25.5-114.0 μg/m3,PM2.5暴露每增加10u

JACC:心梗和心衰再入院与死亡率的变化情况

本研究旨在评估加拿大安大略急性心肌梗死(AMI)和心衰(HF)后再入院率和死亡率的时间趋势,在安大略省,减少医院再入院率并没有政策激励。本研究纳入了2006-2017年65岁以上的AMI和HF住院患者,主要终点事件是30天的再入院率和出院后死亡率。最终共纳入分析了152808名AMI和223283名HF住院患者,安大略的AMI住院率在2006-2017年间降低了32%,HF住院率降低了9.1%。对

盘点:JACC2月第三期研究一览

1. evolocumab治疗家族性高胆固醇血症的远期预后研究DOI: 10.1016/j.jacc.2019.12.020http://www.onlinejacc.org/content/75/6/565对不能达到低密度脂蛋白胆固醇(LDL-C)目标的家族性高胆固醇血症(FH)患者,前蛋白转化酶-枯草杆菌蛋白酶9抑制剂治疗是一种治疗选择。本研究的目的旨在评估evolocumab对纯合F

JACC:基于心电图的肥厚型心肌病人工智能检测算法

肥厚型心肌病(HCM)是一种不常见但重要的心源性猝死原因。本研究的目的旨在开发一种基于12导联心电图(ECG)的HCM人工智能检测方法。本研究利用12导联心电图对2448例确诊为HCM的患者和51153例年龄性别匹配的非HCM对照者进行卷积神经网络(CNN)的检测。随后,CNN会在612名HCM患者和12788名对照进行验证。HCM组患者的平均年龄为54.8 ± 15.9岁,对照组平均年龄为57.

JACC:肠道菌群代谢物水平与冠心病风险密切相关

肠道微生物代谢产物三甲胺氮氧化物(TMAO)与冠状动脉粥样硬化有关,目前尚无前瞻性研究TMAO长期的变化与冠心病发生的相关性。本研究的目的旨在评估10年的血浆TMAO变化与冠心病发生的相关性。本研究在基线水平纳入了760名健康女性,血浆TMAO分别在第一次(1989-1990)和第二次(2000-2002)采血时检测,结果发现尽管基础TMAO水平各异,但是10年的TAMO增加水平与冠心病风险增加密

Baidu
map
Baidu
map
Baidu
map